Development of acute pure red cell aplasia after deferasirox administration in two cases of myelodysplastic syndrome.

Fumihiko Hayakawa, Akihiro Tomita, Tomoki Naoe

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Cases 1 and 2 were 55- and 68-year-old males, respectively. Both were administered deferasirox (DFX) because they received red blood cell transfusions regularly as treatment for myelodysplastic syndrome refractory anemia. DFX administrations were stopped on the 22nd day in case 1 and on the 78th day in case 2 because significantly reduced hemoglobin values and reticulocyte counts were observed. Bone marrow examinations showed pure red cell aplasia in both cases. In case 1, the reticulocyte ratio recovered to the value before drug administration 21 days after drug withdrawal. In case 2, it started increasing on the 14th day, and had recovered to the value before drug administration by the 42nd day after drug withdrawal. Human parvovirus B19 infections were negative in both cases. Both cases were thought to have drug-induced pure red cell aplasia, probably due to DFX. This drug should be used carefully with regular follow-ups of the reticulocyte count.

Original languageEnglish
Pages (from-to)445-449
Number of pages5
Journal[Rinshō ketsueki] The Japanese journal of clinical hematology
Volume55
Issue number4
Publication statusPublished - 01-01-2014
Externally publishedYes

Fingerprint

Pure Red-Cell Aplasia
Myelodysplastic Syndromes
Pharmaceutical Preparations
Reticulocyte Count
Human Parvovirus B19
Refractory Anemia
Parvoviridae Infections
Bone Marrow Examination
Erythrocyte Transfusion
Reticulocytes
deferasirox
Hemoglobins

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

@article{23c156b4d3a9474b8f913068a2690370,
title = "Development of acute pure red cell aplasia after deferasirox administration in two cases of myelodysplastic syndrome.",
abstract = "Cases 1 and 2 were 55- and 68-year-old males, respectively. Both were administered deferasirox (DFX) because they received red blood cell transfusions regularly as treatment for myelodysplastic syndrome refractory anemia. DFX administrations were stopped on the 22nd day in case 1 and on the 78th day in case 2 because significantly reduced hemoglobin values and reticulocyte counts were observed. Bone marrow examinations showed pure red cell aplasia in both cases. In case 1, the reticulocyte ratio recovered to the value before drug administration 21 days after drug withdrawal. In case 2, it started increasing on the 14th day, and had recovered to the value before drug administration by the 42nd day after drug withdrawal. Human parvovirus B19 infections were negative in both cases. Both cases were thought to have drug-induced pure red cell aplasia, probably due to DFX. This drug should be used carefully with regular follow-ups of the reticulocyte count.",
author = "Fumihiko Hayakawa and Akihiro Tomita and Tomoki Naoe",
year = "2014",
month = "1",
day = "1",
language = "English",
volume = "55",
pages = "445--449",
journal = "[Rinsho ketsueki] The Japanese journal of clinical hematology",
issn = "0485-1439",
publisher = "Nihon Rinsho Ketsueki Gakkai/Japan Society of Clinical Hematology",
number = "4",

}

Development of acute pure red cell aplasia after deferasirox administration in two cases of myelodysplastic syndrome. / Hayakawa, Fumihiko; Tomita, Akihiro; Naoe, Tomoki.

In: [Rinshō ketsueki] The Japanese journal of clinical hematology, Vol. 55, No. 4, 01.01.2014, p. 445-449.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Development of acute pure red cell aplasia after deferasirox administration in two cases of myelodysplastic syndrome.

AU - Hayakawa, Fumihiko

AU - Tomita, Akihiro

AU - Naoe, Tomoki

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Cases 1 and 2 were 55- and 68-year-old males, respectively. Both were administered deferasirox (DFX) because they received red blood cell transfusions regularly as treatment for myelodysplastic syndrome refractory anemia. DFX administrations were stopped on the 22nd day in case 1 and on the 78th day in case 2 because significantly reduced hemoglobin values and reticulocyte counts were observed. Bone marrow examinations showed pure red cell aplasia in both cases. In case 1, the reticulocyte ratio recovered to the value before drug administration 21 days after drug withdrawal. In case 2, it started increasing on the 14th day, and had recovered to the value before drug administration by the 42nd day after drug withdrawal. Human parvovirus B19 infections were negative in both cases. Both cases were thought to have drug-induced pure red cell aplasia, probably due to DFX. This drug should be used carefully with regular follow-ups of the reticulocyte count.

AB - Cases 1 and 2 were 55- and 68-year-old males, respectively. Both were administered deferasirox (DFX) because they received red blood cell transfusions regularly as treatment for myelodysplastic syndrome refractory anemia. DFX administrations were stopped on the 22nd day in case 1 and on the 78th day in case 2 because significantly reduced hemoglobin values and reticulocyte counts were observed. Bone marrow examinations showed pure red cell aplasia in both cases. In case 1, the reticulocyte ratio recovered to the value before drug administration 21 days after drug withdrawal. In case 2, it started increasing on the 14th day, and had recovered to the value before drug administration by the 42nd day after drug withdrawal. Human parvovirus B19 infections were negative in both cases. Both cases were thought to have drug-induced pure red cell aplasia, probably due to DFX. This drug should be used carefully with regular follow-ups of the reticulocyte count.

UR - http://www.scopus.com/inward/record.url?scp=84906080197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906080197&partnerID=8YFLogxK

M3 - Article

C2 - 24850456

AN - SCOPUS:84906080197

VL - 55

SP - 445

EP - 449

JO - [Rinsho ketsueki] The Japanese journal of clinical hematology

JF - [Rinsho ketsueki] The Japanese journal of clinical hematology

SN - 0485-1439

IS - 4

ER -